Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans

Borggren, Marie; Nielsen, Jens; Bragstad, Karoline; Karlsson, Ingrid; Krog, Jesper Schak; Williams, James A.; Fomsgaard, Anders

doi:10.1080/21645515.2015.1011987

Cited by 29 publications

(33 citation statements)

References 51 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…al. entitled "Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans" demonstrated that delivery of an influenza antigen gene by a novel vector strategy coupled with a needle-free administration was able to stimulate antigen specific antibody responses to a level similar to those attained by electroporation mediated delivery 12 . The papers then shift to a study on the immune control of serious hemorrhagic filovirus infections, i.e.…”

Section: Please Scroll Down For Articlementioning

confidence: 97%

DNA vaccines 2014 meeting: Highlights and overview

Ugen

Weiner

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Please Scroll Down For Articlementioning

confidence: 97%

DNA vaccines 2014 meeting: Highlights and overview

Ugen

Weiner

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…152 Due to limited transgene expression after DNA vaccination in large animals, vector modifications (e.g., <500 bp bacterial region Nanoplasmid TM vectors; intronic bacterial region MIP vectors) and deliveries (e.g., Electroporation) that improve transgene expression also improve adaptive immunity. 62,125,159 Adapted under a Creative Commons Attribution license from Williams, 2013. 160 incorporation of a 20 bp immunostimulatory ssRNA encoding D type CpG upstream of a 28 bp hairpin dsRNA resulted in a 4-fold increase in antigen reactive IgG titers, 151 and a 2-fold increase in IFN-g secreting CD4 C and CD8 C T cells.…”

Section: Improvements In Dna Plasmid Designmentioning

confidence: 99%

Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

Suschak

Williams

Schmaljohn

2017

Human Vaccines & Immunotherapeutics

186

181

View full text Add to dashboard Cite

A major advantage of DNA vaccination is the ability to induce both humoral and cellular immune responses. DNA vaccines are currently used in veterinary medicine, but have not achieved widespread acceptance for use in humans due to their low immunogenicity in early clinical studies. However, recent clinical data have re-established the value of DNA vaccines, particularly in priming high-level antigen-specific antibody responses. Several approaches have been investigated for improving DNA vaccine efficacy, including advancements in DNA vaccine vector design, the inclusion of genetically engineered cytokine adjuvants, and novel non-mechanical delivery methods. These strategies have shown promise, resulting in augmented adaptive immune responses in not only mice, but also in large animal models. Here, we review advancements in each of these areas that show promise for increasing the immunogenicity of DNA vaccines.

show abstract

“…Commercial devices such as Biojector or Pharmajet have been shown to be able to deliver DNA vaccines in animal models and human trials. A recent study using a rabbit model showed that an influenza DNA vaccine delivered by needle-free IDAL vaccinator elicited a similar antibody response to intradermal electroporation [167]. Another clinical trial used Biojector to deliver an HIV-1 DNA vaccine (VRC-HIVDNA016-00-VP) with good tolerance and priming for CD8+ T cell IFN-γ production and antibody responses after rAd5 boosting [168].…”

Section: Vaccine Deliverymentioning

confidence: 99%

Molecular mechanisms for enhanced DNA vaccine immunogenicity

Petrovsky

2015

Expert Review of Vaccines

252

View full text Add to dashboard Cite

Summary In the two decades since their initial discovery, DNA vaccines technologies have come a long way. Unfortunately, when applied to human subjects inadequate immunogenicity is still the biggest challenge for practical DNA vaccine use. Many different strategies have been tested in preclinical models to address this problem, including novel plasmid vectors and codon optimization to enhance antigen expression, new gene transfection systems or electroporation to increase delivery efficiency, protein or live virus vector boosting regimens to maximise immune stimulation, and formulation of DNA vaccines with traditional or molecular adjuvants. Better understanding of the mechanisms of action of DNA vaccines has also enabled better use of the intrinsic host response to DNA to improve vaccine immunogenicity. This review summarizes recent advances in DNA vaccine technologies and related intracellular events and how these might impact on future directions of DNA vaccine development.

show abstract

Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans

Cited by 29 publications

References 51 publications

DNA vaccines 2014 meeting: Highlights and overview

DNA vaccines 2014 meeting: Highlights and overview

Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

Molecular mechanisms for enhanced DNA vaccine immunogenicity

Contact Info

Product

Resources

About